Follow us on:

Cambridge Cognition Positive pipeline provides ‘Big wins for the business’ (Interview)

Cambridge Cognition Holdings plc (LON:COG) CEO Matthew Stork joins DirectorsTalk to discuss winning increasing numbers of virtual clinical trials during COVID-19. Matthew talks us through the wins and explains what the company will be providing, the benefits of using virtual or part virtual assessments, using these kind of trials after COVID-19 and what we can expect to see from the company in the future.

Cambridge Cognition is a neuroscience technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The company’s software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

Find more news, interviews, share price & company profile here for:Cambridge Cognition Holdings plc

Share this interview

Other Interviews

Cambridge Cognition deliver strong results and robust pipeline (VIDEO) September 27, 2023
Cambridge Cognition growth strategy clearly paying off (VIDEO) May 4, 2023
Cambridge Cognition extends clinical solutions with new acquisition (VIDEO) October 14, 2022
Cambridge Cognition excellent order book, healthy pipeline and further opportunity (VIDEO) September 21, 2022
Cambridge Cognition Holdings strong results and record sales intake (VIDEO) April 13, 2022
Cambridge Cognition Holdings order intake above expectations (Interview) September 21, 2021
Cambridge Cognition – An excellent year for the company (Interview) March 24, 2021
Cambridge Cognition really exciting position and pipeline of opportunities (Interview) September 25, 2020
Cambridge Cognition CEO Matthew Stork Excited over potential for growth (Interview) May 6, 2020
Cambridge Cognition CEO Dr Matthew Stork ‘Strategy paying off’ with significant new contract win (Interview) March 17, 2020

More News

Cambridge Cognition forms new Scientific Advisory Board March 21, 2024
Cambridge Cognition and ActiGraph announce strategic partnership for Advanced CNS Clinical Trials February 21, 2024
Cambridge Cognition appoints Stuart Gall and Philip Rodgers as Non-Executive Directors to support growth plans January 30, 2024
Cambridge Cognition Holdings Grant of Options for Long Term Incentive Plan December 18, 2023
Cambridge Cognition Holdings Changes its Auditor to Crowe UK LLP November 22, 2023
Cambridge Cognition launches its automated quality assurance for clinical trials October 24, 2023
Cambridge Cognition report significant contract for sizeable later stage clinical trial October 11, 2023
Cambridge Cognition positioned to grow revenues and move into profitability September 26, 2023
Cambridge Cognition strengthens balance sheet with £3 million loan September 26, 2023
Cambridge Cognition Holdings Interim Results 26 September 2023 September 4, 2023

Search

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.